|
Basic Characteristics of Mutations
|
|
Mutation Site
|
P1427L |
|
Mutation Site Sentence
|
We found that 3 out of 11 non-synonymous substitutions affected functions (deleterious) of SARS-CoV-2, including P1427L (ORF1b), Y1464C (ORF1b), and Q57H (ORF3a), implying potential changes of fitness of the strains harbouring these mutations (Table 3). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
ORF1b |
|
Standardized Encoding Gene
|
ORF1b
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
MN908947
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
Canada |
|
Literature Information
|
|
PMID
|
33662015
|
|
Title
|
Genomic characterization and evolution of SARS-CoV-2 of a Canadian population
|
|
Author
|
Zhang M,Li L,Luo M,Liang B
|
|
Journal
|
PloS one
|
|
Journal Info
|
2021 Mar 4;16(3):e0247799
|
|
Abstract
|
COVID-19 has greatly affected public health and world economy. In this study, we analyzed 129 full-length genomes of SARS-CoV-2 viruses of a Canadian population during early phase of the pandemic. Phylogenetic analysis revealed three major paths of transmission of SARS-CoV-2 viruses into Canada. Twenty-one substitutions that have frequencies greater than 3% of viral population were identified. Analysis of these substitutions indicated that P1427I (ORF1b), Y1464C (ORF1b), and Q57H (ORF3a) might affect functions of the corresponding SARS-CoV-2 encoded proteins. Additionally, we found the evidence of positive selection on the ORF3a and codon 614 of Spike protein, suggesting the viral components responsible for host entry and activation of inflammation response were targeted by host immune responses. The study showed genomic variation and evolution of SARS-CoV-2 in a Canadian population. These information may help develop preventive strategies and be used for further study of SARS-CoV-2 pathogenesis and therapeutics development.
|
|
Sequence Data
|
-
|